Molecular structure of Palonosetron hydrochloride, CAS Number: 135729-62-3
Palonosetron hydrochloride (CAS 135729-62-3)
See product citations (4)
Alternate Names:
(3aS)-2-(3S)-1-Azabicyclo[2.2.2]oct-3-yl-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one Hydrochloride Aloxi Onicit RS-25259-197
Application:
Palonosetron hydrochloride is a serotonin 5-HT3 receptor antagonist
CAS Number:
135729-62-3
Purity:
≥99%
Molecular Weight:
332.87
Molecular Formula:
C19H24N2O•HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Palonosetron Hydrochloride is widely used in chemical research, particularly in studies focusing on receptor binding and signal transduction mechanisms. Its role as a serotonin receptor antagonist makes it useful for understanding the interactions at serotonin receptors, which are for various biological processes. Researchers utilize Palonosetron Hydrochloride to explore the molecular dynamics and conformational changes of these receptors, providing insights into their function and regulation. Additionally, this compound is employed in the study of neurotransmitter release, where it helps elucidate the pathways and mechanisms involved in neuronal communication. In materials science, Palonosetron Hydrochloride is also used in the development of sensor technology, where it is applied to create sensitive components for detecting neurotransmitters and other biological markers.
Palonosetron hydrochloride (CAS 135729-62-3) References
- Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration. | Trissel, LA., et al. 2007. Am J Health Syst Pharm. 64: 1209-13. PMID: 17519464
- Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration. | Kupie, TC., et al. 2008. Am J Health Syst Pharm. 65: 1735-59. PMID: 18769000
- [Pharmacological, pharmacokinetic, and clinical profile of palonosetron hydrochloride (ALOXI I.V. Injection 0.75 mg), a novel antiemetic 5-HT3-receptor antagonist]. | Ajioka, H., et al. 2010. Nihon Yakurigaku Zasshi. 136: 113-20. PMID: 20702972
- The effect of palonosetron hydrochloride in the prevention of chemotherapy-induced moderate and severe nausea and vomiting. | Huang, J., et al. 2013. Exp Ther Med. 5: 1418-1426. PMID: 23737892
- Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated y-site administration. | Trissel, LA. and Xu, QA. 2005. Int J Pharm Compd. 9: 238-41. PMID: 23924983
- Physical and chemical stability of palonosetron hydrochloride with Fluorouracil and with gemcitabine hydrochloride during simulated y-site administration. | Trissel, LA. and Zhang, Y. 2005. Int J Pharm Compd. 9: 320-2. PMID: 23925056
- Compatibility and stability of palonosetron hydrochloride with four neruomuscular blocking agents during simulated y-site administration. | Trusley, C., et al. 2008. Int J Pharm Compd. 12: 156-60. PMID: 23969608
- Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated y-site administration. | Kupiec, TC., et al. 2008. Int J Pharm Compd. 12: 170-3. PMID: 23969611
- Physical and chemical stability of palonosetron hydrochloride with glycopyrrolate and neostigmine during simulated y-site administration. | Ben, M., et al. 2008. Int J Pharm Compd. 12: 368-71. PMID: 23969774
- Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration. | Ben, M., et al. 2008. Int J Pharm Compd. 12: 460-2. PMID: 23969872
- Compatibility and stability of palonosetron hydrochloride and propofol during simulated y-site administration. | Trissel, LA., et al. 2009. Int J Pharm Compd. 13: 78-80. PMID: 23969967
- Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated y-site administration. | Trissel, LA., et al. 2006. Int J Pharm Compd. 10: 234-6. PMID: 23974237
- Palonosetron hydrochloride compatiblity and stability with three B-lactam anitbiotic during simulated y-site adminstration. | Ben, M., et al. 2007. Int J Pharm Compd. 11: 520-4. PMID: 23994813
- In vitro inhibitory effects of palonosetron hydrochloride, bevacizumab and cyclophosphamide on purified paraoxonase-I (hPON1) from human serum. | Türkeş, C., et al. 2016. Environ Toxicol Pharmacol. 42: 252-7. PMID: 26915059
- Effect of low-dose esketamine on pain control and postpartum depression after cesarean section: a retrospective cohort study. | Wang, Y., et al. 2022. Ann Palliat Med. 11: 45-57. PMID: 35144397
Inhibitor of:
SR-3A.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Palonosetron hydrochloride, 10 mg | sc-212521 | 10 mg | $95.00 |